Metabolomics in acute myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Metabolomics
• Cancer Biology

Background:

• Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy driven by genetic mutations affecting myeloid cell differentiation and proliferation.
• Patient outcomes and treatment responses in AML are highly variable, influenced by specific chromosomal and molecular alterations.
• Diverse platforms are utilized for AML characterization and stratification.

Purpose of the Study:

• To review significant metabolomic studies in AML conducted over the past decade.
• To highlight the role of metabolic reprogramming in AML pathogenesis and clinical relevance.
• To explore the application of metabolomic findings in developing novel therapeutic strategies for AML.

Main Methods:

• Comprehensive literature review focusing on metabolomic profiling of acute myeloid leukemia.
• Analysis of studies examining small molecule profiles in biological samples related to AML.
• Synthesis of data on the clinical applications of metabolomics in AML diagnosis, risk stratification, and drug development.

Main Results:

• Metabolomics has emerged as a critical tool for understanding the metabolic dependencies of cancer cells, including those in AML.
• Metabolic reprogramming is a key feature of AML, impacting disease progression and patient outcomes.
• Metabolomic insights have demonstrated clinical relevance for AML diagnosis, risk stratification, and the identification of therapeutic targets.

Conclusions:

• Metabolomics provides valuable insights into the complex biology of acute myeloid leukemia.
• The study of metabolic alterations in AML holds significant promise for advancing diagnostic accuracy and patient risk assessment.
• Metabolomic data is crucial for the development of targeted therapies and novel treatment strategies for AML patients.